Acrivon Therapeutics: Strong Buy on Impressive Clinical Outcomes and Market Potential

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report), with a price target of $22.00.

Soumit Roy has given his Buy rating due to a combination of factors surrounding Acrivon Therapeutics, Inc.’s clinical data and potential in the healthcare market. The efficacy of Acrivon’s monotherapy treatments for late-stage ovarian and endometrial cancer patients has been notably high, particularly in those who are positive for OncoSig—a biomarker used by Acrivon. In ovarian cancer, the objective response rate (ORR) was 40%, which is substantially higher than the 12-15% ORR for standard chemotherapy. For endometrial cancer, the ORR was 60%, compared to the 20-25% with standard care, signaling a strong performance of the drug in difficult-to-treat cases.

Moreover, the safety profile of the drug appears to be manageable and has shown improvement compared to prior clinical data. This includes a reduction in severe side effects such as thrombocytopenia and neutropenia. The potential to expand the addressable patient population is also a positive factor, as the OncoSig negative data showed the drug to be active, with stable disease rates and tumor reductions nearing the 30% mark in a significant portion of patients. These factors, alongside the possibility of enhancing treatment strategies through combination regimens or dose adjustments, contribute to the optimism for deeper therapeutic responses, thereby justifying the Buy rating for Acrivon Therapeutics, Inc.’s stock.

Roy covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Acrivon Therapeutics, Inc., and Cassava Sciences. According to TipRanks, Roy has an average return of -6.6% and a 26.77% success rate on recommended stocks.

In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Acrivon Therapeutics, Inc. (ACRV) Company Description:

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.